Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Spinal injury study seeks to unlock vaccine secrets

NCT ID NCT05869968

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares immune responses to flu and COVID-19 vaccines between people with chronic spinal cord injuries and healthy individuals. Researchers will analyze blood samples to see if gene activity and antibody levels differ between the groups. The goal is to understand why people with spinal cord injuries face higher infection risks and how vaccines can work better for them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why people with spinal cord injuries are more prone to infections and how to better protect them through vaccines.
What could go wrong
This is an observational study, not a treatment trial. It will not directly improve health, and results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be adults (ages 18-89 years old) with SCI or who are uninjured controls who are electing to receiving flu or COVID-19 vaccines to promote their health.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria SCI Participant Inclusion Criteria: To be eligible for prospective enrollment, participants are required to meet the following inclusion criteria: * 18-89 years old with traumatic SCI * initial traumatic SCI \>/=1 year from enrollment (DOD funded study) * initial traumatic SCI \<1 year from enrollment (non-DOD funded pilot study) * American Spinal Injury Association (ASIA) classification grade A-D * Neurological Injury Level C1-T10 * Demonstrate capacity to provide informed consent using the "teach back" method to verify understanding and appreciation of study objectives and procedures. Exclusion Criteria To be eligible for prospective enrollment, SCI participants are required to not meet the following exclusion criteria: * Stage III-IV pressure ulcers * Cancer, chemotherapy, neutropenia * Pregnancy or lactation * No known SCI * Autoimmune disease * Pre-existing neurological disease * History of dementia * Any other condition that would compromise their ability to provide informed consent * Any other condition that a study physician feels would preclude participation or be contraindicated Uninjured Control Group: Inclusion Criteria Uninjured Control Participant Inclusion Criteria: To be eligible for prospective enrollment, participants are required to meet the following inclusion criteria: * 18-89 years old without traumatic SCI * Demonstrate capacity to provide informed consent using the "teach back" method to verify understanding and appreciation of study objectives and procedures. Exclusion Criteria To be eligible for prospective enrollment, uninjured control participants are required to not meet the following exclusion criteria: * Cancer, chemotherapy, neutropenia * Pregnancy or lactation * Autoimmune disease * Pre-existing neurological disease * History of dementia * Any other condition that would compromise their ability to provide informed consent * Any other condition that a study physician feels would preclude participation or be contraindicated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 vaccine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwell Health

    Manhasset, New York, 11030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.